Allogene Therapeutics (ALLO) Long-Term Deferred Tax (2019 - 2021)

Allogene Therapeutics (ALLO) posted Long-Term Deferred Tax of $224.3 million for Q4 2021, up 315.14% sequentially from $54.0 million in Q4 2019.

Allogene Therapeutics (ALLO) Long-Term Deferred Tax (2019 - 2021) Analysis & Trends

Allogene Therapeutics has reported Long-Term Deferred Tax for 2 years, with the latest figure at $224.3 million in Q4 2021.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $224.3 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $224.3 million (changed N/A YoY) and the FY2021 annual result came in at $224.3 million, changed N/A from the prior year.
Long-Term Deferred Tax improved to $224.3 million in Q4 2021 per ALLO's latest filing, from $54.0 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $224.3 million in Q4 2021 and troughed at $54.0 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Allogene Therapeutics	707.96 Mn	707.96 Mn	-

Download Data

Date	Value
Dec 31, 2021	224.25 Mn
Dec 31, 2019	54.02 Mn